A 25% drop in airway clearance revenue, tied to a distributor inventory transition around the new AffloVest, pushed Tactile Medical below expectations on both lines. Management reaffirmed full-year revenue guidance and raised its adjusted EBITDA outlook, framing the shortfall as timing.
Tactile Systems Technology Inc
TCMD at a Glance
- Market cap
- $600.6M
- P/E ratio
- 26.0
- Revenue (TTM)
- $356.4M
- Profit margin
- 6.7%
- EPS (TTM)
- $1.03
- 52-week range
- $21 – $38
- Street target
- $36.33
- Next report
- Feb 16, 2027
Headquartered in Minneapolis, MN Fiscal year ends December NASDAQ: TCMD tactilemedical.com
About Tactile Systems Technology
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company. It develops and markets at-home therapies for people with underserved chronic conditions, including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions.
Its business has two product lines:
- **Lymphedema products** (89% of Q3 2026 revenue): basic and advanced pneumatic compression systems, including the Flexitouch system, plus the LymphaTech 3D Scanner. The scanner recently received an expanded FDA clearance to aid in assessing lymphedema.
- **Airway clearance products**: the AffloVest high-frequency chest wall oscillation vest, whose next-generation system launched in Q2 2026.
The company generates both sales and rental revenue and relies on reimbursement from third-party payers. It sells through direct and DME channels. It works with clinicians to expand clinical evidence, raise awareness and increase access to care.
The company has a pending 510(k) submission for Flexitouch Pro. It completed an acquisition in 2026 and has no outstanding borrowings under its credit agreement. Updated
Frequently Asked Questions
What does Tactile Systems Technology do?
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company. It develops and markets at-home therapies for people with underserved chronic conditions, including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions.
What is the TCMD stock price target?
The Wall Street consensus 12-month price target for TCMD is $36.33.